NovaGene Therapeutics
Healthy100/100Mid-sizeBiotechnology
About this account
Gene-therapy biotech, first BLA in 18 months, lean RA team.
Relationship health
100/100 · HealthyHow this account's health has moved over the last 5 weeks.
100 pts0 pts
4w ago2w agothis week
How touches have landed
Every logged touch with NovaGene Therapeutics, by outcome.
Interested1100%
Company profile
Not analyzed yet — analyze to qualify its type, ownership and revenue from the web, and the offerings that fit show automatically.
Agent briefing
NovaGene Therapeutics is in good shape — healthy, with $270K of open pipeline to grow. It's single-threaded, so widening the relationship would de-risk the deal. Recommended next move: Re-engage NovaGene Therapeutics.
HealthHealthy (100/100).
Pipeline1 open deal worth $270K.
ThreadingSingle-threaded on Dana Whitfield — widen the relationship to de-risk.
MomentumLast touch Jul 3, 2026 • 1:49 PM.
Recommended: Re-engage NovaGene Therapeutics
Key Contacts
Value PropositionsAI generated
Clinical Trial Regulatory Support80% match
Position Clinical Trial Regulatory Support against NovaGene Therapeutics's near-term regulatory milestones.
Matched from your Freyr knowledge base
Regulatory Intelligence60% match
Single-pane monitoring across FDA, EMA and 120+ agencies.
Matched from your Freyr knowledge base
Angles to researchAI generated
Agent-suggested things worth checking before you reach out — verify before you rely on them.
Regulatory
Check for recent Biotechnology guidance that could tighten their submission timelines — a timely reason to reach out.
Hiring
See whether NovaGene is hiring in regulatory affairs — a growing team often means more submission workload they may need help with.